PEG-GHRF - Serono

Drug Profile

PEG-GHRF - Serono

Alternative Names: pegylated growth hormone releasing factor; Pegylated growth hormone releasing factor - Serono

Latest Information Update: 26 Jan 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Serono
  • Class
  • Mechanism of Action Growth hormone releasing factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Growth disorders

Most Recent Events

  • 22 Dec 2004 Discontinued - Phase-I for Growth disorders in Switzerland (unspecified route)
  • 12 Jun 2003 Phase-I clinical trials in Growth disorders in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top